Amryt Pharma PLC - ESG Rating & Company Profile powered by AI
This report of Amryt Pharma PLC was assembled by All Street Sevva using proprietary NLP. This assessment of Amryt Pharma PLC employs information from across the web and also from available disclosures by Amryt Pharma PLC. Detailed Sustainability assessment of Amryt Pharma PLC can be reached by logging in.
Amryt Pharma PLC in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.1; made up of an environmental score of 4.0, social score of 6.4 and governance score of 8.0.
6.1
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 450 | Valneva USA Inc | 6.2 | High |
| 450 | Sino Biopharmaceutical Ltd | 6.2 | High |
| 483 | Amryt Pharma PLC | 6.1 | High |
| 483 | Bora Pharmaceuticals Co Ltd | 6.1 | High |
| 483 | Affimed NV | 6.1 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Amryt Pharma PLC have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Amryt Pharma PLC disclose current and historical energy intensity?
Sign up for free to unlockDoes Amryt Pharma PLC report the average age of the workforce?
Sign up for free to unlockDoes Amryt Pharma PLC reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Amryt Pharma PLC disclose its ethnicity pay gap?
Sign up for free to unlockDoes Amryt Pharma PLC disclose cybersecurity risks?
Sign up for free to unlockDoes Amryt Pharma PLC offer flexible work?
Sign up for free to unlockDoes Amryt Pharma PLC have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Amryt Pharma PLC disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Amryt Pharma PLC conduct supply chain audits?
Sign up for free to unlockDoes Amryt Pharma PLC disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Amryt Pharma PLC conduct 360 degree staff reviews?
Sign up for free to unlockDoes Amryt Pharma PLC disclose the individual responsible for D&I?
Sign up for free to unlockDoes Amryt Pharma PLC disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Amryt Pharma PLC disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Amryt Pharma PLC disclose water use targets?
Sign up for free to unlockDoes Amryt Pharma PLC have careers partnerships with academic institutions?
Sign up for free to unlockDid Amryt Pharma PLC have a product recall in the last two years?
Sign up for free to unlockDoes Amryt Pharma PLC disclose incidents of discrimination?
Sign up for free to unlockDoes Amryt Pharma PLC allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Amryt Pharma PLC issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Amryt Pharma PLC disclose parental leave metrics?
Sign up for free to unlockDoes Amryt Pharma PLC disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Amryt Pharma PLC disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Amryt Pharma PLC disclose the pay ratio of women to men?
Sign up for free to unlockDoes Amryt Pharma PLC support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Amryt Pharma PLC disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Amryt Pharma PLC reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Amryt Pharma PLC involved in embryonic stem cell research?
Sign up for free to unlockDoes Amryt Pharma PLC disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Amryt Pharma PLC disclose its waste policy?
Sign up for free to unlockDoes Amryt Pharma PLC report according to TCFD requirements?
Sign up for free to unlockDoes Amryt Pharma PLC disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Amryt Pharma PLC disclose energy use targets?
Sign up for free to unlockDoes Amryt Pharma PLC disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Amryt Pharma PLC have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Amryt Pharma PLC
These potential risks are based on the size, segment and geographies of the company.
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the rare cholesterol disorder. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.